Table 2.
Characteristics of eye involvement distinguished by different biosimilars employed at the time of the switch.
| Biosimilars employed | Non-Anterior Uveitis, n (%) | Patients with BD, n (%) | Patients with idiopathic uveitis, n (%) | BCVA, mean ± SD | CMT, mean ± SD |
UME, n (%) | Retinal vasculitis, n (%) | Eyes with uveitic complications, n (%) | cDMARDs coadministered, n (%) | Eyes with flares during the 12 months before, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Flixabi® (n = 16) | 12 (75) | 13 (81.3) | 3 (18.8) | 7.23 ± 2.4 | 288.6 ± 35.6 | 5 (31.3) | 6 (37.5) | 4 (25) | 5 (31.3) | 3 (18.8) |
| Inflectra® (n = 9) | 9 (100) | 9 (100) | 0 (0) | 6.9 ± 4.2 | 295 ± 30.3 | 2 (22.2) | 0 (0) | 3 (33.3) | 2 (22.2) | 1 (11.1) |
| Imraldi® (n = 33) | 22 (66.7) | 22 (66.7) | 4 (12.1) | 9.3 ± 1.9 | 275.9 ± 43.1 | 2 (6.1) | 0 (0) | 5 (15.2) | 7 (21.2) | 7 (21.2) |
| Benepali® (n = 4) | 1 (25) | 0 (0) | 0 (0) | 6.5 ± 2.1 | 287.5 ± 24.7 | 0 (0) | 0 (0) | 0 (0) | 2 (50) | 0 (0) |
BCVA, best corrected visual acuity; BD, Behçet’s disease; cDMARDs, conventional disease modifying anti-rheumatic drugs; CMT, central macular thickness; n, number of eyes; UME, uveitic macular edema.